Page 21 - The DHEA Debate - Life Extensions Magazine

47. Wang TT, Hursting SD, Perkins SN, Phang JM. Effects of dehydroepiandrosterone and
calorie restriction on the Bcl-2/Bax- mediated apoptotic pathway in p53-deficient mice. Cancer
Lett. 1997 Jun 3;116(1):61-9.

48. Aoki K, Nakajima A, Mukasa K, Osawa E, Mori Y, Sekihara H. Prevention of diabetes,
hepatic injury, and colon cancer with dehydroepiandrosterone. J Steroid Biochem Mol Biol. 2003
Jun;85(2-5):469- 72.
49. Marx C, Petros S, Bornstein SR, et al. Adrenocortical hormones in survivors and
nonsurvivors of severe sepsis: diverse time course of dehydroepiandrosterone, dehy-
droepiandrosterone-sulfate, and cortisol. Crit Care Med. 2003 May;31(5):1382-8.
50. Barret-Conner E, Knaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate,
mortality and cardiovascular disease. N Engl J Med. 1986 Dec 11; 315(24):1519-24.
51. Mulder JW, Frissen PH, Kirjnen P, et al. Dehydroepiandrosterone as predictor for
progression to AIDS in asymptomatic HIV-infected men. J Infect Dis. 1992; 165(3):413-418.
52. Yasushi M, Hirofumi Y, Michihiro Y, Yuki M, Koichi N, et al. Plasma levels of
dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion
to the severity. J Clin Endocrinol Metab. 2000 May; 85(5):1834-40.

53. Nagai T, Noda Y, Nozaki A, Nabeshima T. Neuroactive steroid and stress response. Nihon
Shinkei Seishin Yakurigaku Zasshi. 2001 Nov;21(5):157-62.
54. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous
hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003 Jan 1;157(1):25-31.
55. Solerte SB, Fioravanti M, Vignati G, Giustina A, Cravello L, Ferrari E. DHEA sulfate
enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-
like growth factor I. J Clin Endocrinol Metab. 1999 Sep;84(9):3260-7.

56. Khorram O, Vu L, Yen SS. Activation of immune function by dehydroepiandrosterone
(DHEA) in age-advanced men. J Gerontol A Biol Sci Med Sci. 1997 Jan;52(1):M1-7.

57. Assan R, Robel P, Baulieu EE. Dehydroepiandrosterone (DHEA) for diabetic patients? Eur J
Endocrinol. 1996 Jul; 135(1):37-8.
58. Casson PR, Hornsby PJ, Buster JE. Adrenal androgens, insulin resistance, and
cardiovascular disease. Semin Reprod Endocrinol. 1996 Feb;14(1):29-34.
59. Beer NA, Jakubowicz DJ, Matt DW, Beer RM, Nestler JE. Dehydroepiandrosterone reduces
plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men.
Am J Med Sci. 1996 May;311(5):205-10

60. Casson PR, Anderson RN, Herrod HG, et al. Oral dehydroepiandrosterone in physiologic
doses modulates immune function in postmenopausal women. Am J Obstet Gynecol. 1993 Dec;
169(6):1536-9.

61. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild
to moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-
controlled trial. Arthritis Rheum. 2002 Nov; 46(11):2924-7.
62. Gelato MC. Aging and immune function: a possible role for growth hormone. Horm Res.
1996;45(1-2):46-9.